Erratum: Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade (Cancer Cell (2018) 33(5) (922–936.e10), (S1535610818301740), (10.1016/j.ccell.2018.04.003))

(Cancer Cell 33, 922–936.e1–e10; May 14, 2018) We reported the generation of a bispecific antibody against HER2 and HER3 using an unbiased combinatorial screening approach. During the preparation of the manuscript, we unintentionally introduced an error in Figure 2C and its legend, where a treatment arm was incorrectly labeled as “MM-121” and should have been “PG3178.” We have now corrected Figure 2 and its corresponding legend, shown here. In the Results section, when describing the results presented in Figure 2C, “PG3178” was again incorrectly referenced as “MM-121”. The corrected text reads as follows: “As previously reported for the tyrosine kinase inhibitor lapatinib (Wilson et al., 2012), the inhibitory activity of HER3 mAb PG3178 (2 nM, Figure 2C) was reduced in a dose-dependent manner as the HRG concentration increased beyond its EC₉₀ value for growth stimulation (0.11 nM)”. The other references to the analog of MM-121 in the manuscript are correct. We apologize for any confusions this error may have caused.[Figure